发明申请
US20110008325A1 Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid Prepared from a Unit Dose Suspension
审中-公开
含有单体剂量悬浮液制备的磺基烷基醚环糊精和皮质类固醇的吸入制剂
- 专利标题： Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid Prepared from a Unit Dose Suspension
- 专利标题（中）： 含有单体剂量悬浮液制备的磺基烷基醚环糊精和皮质类固醇的吸入制剂
-
申请号： US12835174申请日： 2010-07-13
-
公开(公告)号： US20110008325A1公开(公告)日： 2011-01-13
- 发明人: James D. Pipkin , Rupert O. Zimmerer , Diane O. Thompson , Gerold L. Mosher
- 申请人： James D. Pipkin , Rupert O. Zimmerer , Diane O. Thompson , Gerold L. Mosher
- 申请人地址： US KS Lenexa
- 专利权人： CyDex Pharmaceuticals, Inc.
- 当前专利权人： CyDex Pharmaceuticals, Inc.
- 当前专利权人地址： US KS Lenexa
- 主分类号： A61K31/724
- IPC分类号： A61K31/724 ; A61K39/395 ; A61P11/00
摘要：
An inhalable unit dose liquid formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of corticosteroid, such as budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus. The formulation is prepared by mixing SAE-CD, in solid or liquid (dissolved) form, with an inhalable suspension-based unit dose formulation.
信息查询
